Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page’s release/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a maintenance or platform update rather than a change to the study content.SummaryDifference0.1%

- Check25 days agoChange DetectedAdded Revision: v3.5.2; Removed Revision: v3.5.0.SummaryDifference0.1%

- Check54 days agoChange DetectedVersion update from v3.4.3 to v3.5.0; study details, eligibility criteria, and outcomes remain unchanged.SummaryDifference0.1%

- Check68 days agoChange DetectedRevision 3.4.3 was added and 3.4.2 was removed. No study details or interactive elements appear to be altered.SummaryDifference0.1%

- Check89 days agoChange DetectedRevision: v3.4.2 was added and v3.4.1 was removed. This appears to be a maintenance/version update that does not modify study details or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check97 days agoChange DetectedRevision update: v3.4.1 added, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.